This Article Abstract Full Text Full Text (PDF) View study sites and investigators Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brass, E. P. Articles by Hiatt, W. R. Search for Related Content PubMed Articles by Brass, E. P. Articles by Hiatt, W. R.

The Novel Phosphodiesterase Inhibitor NM-702 Improves Claudication-Limited Exercise Performance in Patients With Peripheral Arterial Disease

Eric P. Brass, MD, PhD^_*,_*, Richard Anthony, PhD, Frederick R. Cobb, MD, Isao Koda, PhD, Jenny Jiao, PhD and William R. Hiatt, MD^||

^_* Department of Medicine, Harbor-UCLA Medical Center, Torrance, California
Catalyst Pharmaceutical Research, Inc., Pasadena, California
Nissan Chemical America, Pasadena, California
Durham VA Medical Center, Durham, North Carolina
^|| University of Colorado, Divisions of Geriatrics and Cardiology, and the Colorado Prevention Center, Denver, Colorado

View larger version (9K): [in this window] [in a new window] [Download PPT slide]   Figure 1 The percent change in peak walking time as a function of time. Data are mean values ± SEM for the intention to treat population with missing data replaced by last observation carried forward. Solid circles = placebo group; open squares = 4-mg NM-702 group; open triangles = 8-mg NM-702 group.